应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
XFOR X4制药
盘前交易 12-19 05:46:34 EST
0.6411
-0.0976
-13.21%
盘前
0.6411
+0.0000
0.00%
05:08 EST
最高
0.8270
最低
0.6212
成交量
252.63万
今开
0.7201
昨收
0.7387
日振幅
27.86%
总市值
1.09亿
流通市值
8,329万
总股本
1.71亿
成交额
176.30万
换手率
1.94%
流通股本
1.30亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
X4制药盘中异动 早盘股价大涨5.59%
市场透视 · 12-18 22:35
X4制药盘中异动 早盘股价大涨5.59%
X4制药盘中异动 早盘大幅上涨8.64%
市场透视 · 12-16 22:32
X4制药盘中异动 早盘大幅上涨8.64%
X4制药盘中异动 早盘股价大涨5.56%报0.634美元
市场透视 · 12-13
X4制药盘中异动 早盘股价大涨5.56%报0.634美元
X4制药盘中异动 早盘快速上涨5.19%报0.800美元
市场透视 · 12-12
X4制药盘中异动 早盘快速上涨5.19%报0.800美元
X4制药盘中异动 早盘大幅跳水6.36%
市场透视 · 12-11
X4制药盘中异动 早盘大幅跳水6.36%
X4制药盘中异动 快速拉升6.08%
市场透视 · 12-10
X4制药盘中异动 快速拉升6.08%
X4制药盘中异动 早盘急速拉升7.74%
市场透视 · 12-09
X4制药盘中异动 早盘急速拉升7.74%
X4制药盘中异动 早盘股价大涨5.40%报0.410美元
市场透视 · 12-06
X4制药盘中异动 早盘股价大涨5.40%报0.410美元
X4制药盘中异动 大幅上涨5.08%报0.389美元
市场透视 · 12-05
X4制药盘中异动 大幅上涨5.08%报0.389美元
X4制药盘中异动 早盘大幅跳水5.07%报0.352美元
市场透视 · 12-03
X4制药盘中异动 早盘大幅跳水5.07%报0.352美元
X4制药盘中异动 临近收盘股价大跌5.27%报0.372美元
市场透视 · 12-03
X4制药盘中异动 临近收盘股价大跌5.27%报0.372美元
X4制药盘中异动 临近收盘急速上涨5.02%报0.370美元
市场透视 · 11-28
X4制药盘中异动 临近收盘急速上涨5.02%报0.370美元
X4制药盘中异动 大幅拉升5.45%
市场透视 · 11-27
X4制药盘中异动 大幅拉升5.45%
X4制药盘中异动 早盘大幅上涨5.06%报0.355美元
市场透视 · 11-25
X4制药盘中异动 早盘大幅上涨5.06%报0.355美元
X4制药盘中异动 大幅跳水5.18%报0.349美元
市场透视 · 11-22
X4制药盘中异动 大幅跳水5.18%报0.349美元
X4制药盘中异动 临近收盘股价大涨5.14%报0.358美元
市场透视 · 11-22
X4制药盘中异动 临近收盘股价大涨5.14%报0.358美元
X4制药2024财年第三财季实现净利润-36.70百万美元,同比减少1488.74%
市场透视 · 11-22
X4制药2024财年第三财季实现净利润-36.70百万美元,同比减少1488.74%
X4制药盘中异动 早盘急速下挫7.09%
市场透视 · 11-20
X4制药盘中异动 早盘急速下挫7.09%
X4制药盘中异动 股价大跌7.46%
市场透视 · 11-18
X4制药盘中异动 股价大跌7.46%
X4制药盘中异动 股价大跌5.24%
市场透视 · 11-15
X4制药盘中异动 股价大跌5.24%
暂无数据
公司概况
公司名称:
X4制药
所属市场:
NASDAQ
上市日期:
--
主营业务:
X4 Pharmaceuticals, Inc.于2010年8月2日根据特拉华州法律注册成立。该公司是一家晚期临床阶段的生物制药公司,发现和开发用于治疗罕见疾病和治疗选择有限的疾病的新疗法,重点关注免疫系统功能障碍导致的疾病。公司主导临床候选药物为mavorixafor,一种趋化因子受体CXCR4的小分子选择性拮抗剂。由于mavorixafor能够增加成熟、功能性白细胞进入血液的动员,他们认为mavorixafor有可能在多种慢性中性粒细胞减少性疾病中提供治疗益处,包括WHIM综合征,这是一种罕见的原发性免疫缺陷。
发行价格:
--
{"stockData":{"symbol":"XFOR","market":"US","secType":"STK","nameCN":"X4制药","latestPrice":0.6411,"timestamp":1734555600000,"preClose":0.7387,"halted":0,"volume":2526341,"hourTrading":{"tag":"盘前","latestPrice":0.6411,"preClose":0.6411,"latestTime":"05:08 EST","volume":1547,"amount":991.7761308,"timestamp":1734602914712},"delay":0,"floatShares":129912749,"shares":170546469,"eps":-0.085969,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.0976,"latestTime":"12-19 05:46:34 EST","open":0.7201,"high":0.827,"low":0.6212,"amount":1762968.0348815501,"amplitude":0.278598,"askPrice":0.7393,"askSize":100,"bidPrice":0.64,"bidSize":25000,"shortable":0,"etf":0,"ttmEps":-0.085969,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734618600000},"adr":0,"listingDate":1510808400000,"adjPreClose":0.6411,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":0.6411,"preClose":0.6411,"latestTime":"05:08 EST","volume":1547,"amount":991.7761308,"timestamp":1734602914712},"postHourTrading":{"tag":"盘后","latestPrice":0.6837,"preClose":0.6411,"latestTime":"19:37 EST","volume":21358,"amount":14413.9678,"timestamp":1734568671747},"volumeRatio":0.5046687141389513,"impliedVol":2.767,"impliedVolPercentile":0.8884},"requestUrl":"/m/hq/s/XFOR/tweets","defaultTab":"tweets","newsList":[{"id":"2492181672","title":"X4制药盘中异动 早盘股价大涨5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492181672","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492181672?lang=zh_cn&edition=full","pubTime":"2024-12-18 22:35","pubTimestamp":1734532506,"startTime":"0","endTime":"0","summary":"北京时间2024年12月18日22时35分,X4制药股票出现异动,股价急速上涨5.59%。截至发稿,该股报0.780美元/股,成交量5.674万股,换手率0.03%,振幅6.58%。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。X4制药股票所在的生物技术行业中,整体跌幅为0.03%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121822350795ea54ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121822350795ea54ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2491069402","title":"X4制药盘中异动 早盘大幅上涨8.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491069402","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491069402?lang=zh_cn&edition=full","pubTime":"2024-12-16 22:32","pubTimestamp":1734359537,"startTime":"0","endTime":"0","summary":"北京时间2024年12月16日22时32分,X4制药股票出现波动,股价快速上涨8.64%。截至发稿,该股报0.728美元/股,成交量13.9637万股,换手率0.08%,振幅8.61%。X4制药股票所在的生物技术行业中,整体跌幅为0.05%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216223217a1f342fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216223217a1f342fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2491371477","title":"X4制药盘中异动 早盘股价大涨5.56%报0.634美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491371477","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491371477?lang=zh_cn&edition=full","pubTime":"2024-12-13 22:31","pubTimestamp":1734100317,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日22时31分,X4制药股票出现波动,股价快速上涨5.56%。截至发稿,该股报0.634美元/股,成交量10.0136万股,换手率0.06%,振幅3.05%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-7.73倍。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。X4制药股票所在的生物技术行业中,整体跌幅为0.16%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213223157984bd67e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213223157984bd67e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2490384618","title":"X4制药盘中异动 早盘快速上涨5.19%报0.800美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490384618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490384618?lang=zh_cn&edition=full","pubTime":"2024-12-12 22:31","pubTimestamp":1734013870,"startTime":"0","endTime":"0","summary":"北京时间2024年12月12日22时31分,X4制药股票出现异动,股价急速上涨5.19%。截至发稿,该股报0.800美元/股,成交量17.4811万股,换手率0.10%,振幅0.03%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-10.00倍。X4制药股票所在的生物技术行业中,整体跌幅为0.10%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212223110ab72a7d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212223110ab72a7d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2490591861","title":"X4制药盘中异动 早盘大幅跳水6.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490591861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490591861?lang=zh_cn&edition=full","pubTime":"2024-12-11 22:38","pubTimestamp":1733927892,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日22时38分,X4制药股票出现波动,股价大幅下挫6.36%。截至发稿,该股报0.631美元/股,成交量26.6985万股,换手率0.16%,振幅5.66%。X4制药股票所在的生物技术行业中,整体涨幅为0.01%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223812a1e66de1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223812a1e66de1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2490433130","title":"X4制药盘中异动 快速拉升6.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490433130","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490433130?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:31","pubTimestamp":1733841069,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时31分,X4制药股票出现异动,股价快速拉升6.08%。截至发稿,该股报0.560美元/股,成交量12.16万股,换手率0.07%,振幅0.91%。X4制药股票所在的生物技术行业中,整体跌幅为0.25%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223109984b0bac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223109984b0bac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2490793327","title":"X4制药盘中异动 早盘急速拉升7.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490793327","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490793327?lang=zh_cn&edition=full","pubTime":"2024-12-09 22:33","pubTimestamp":1733754781,"startTime":"0","endTime":"0","summary":"北京时间2024年12月09日22时33分,X4制药股票出现波动,股价快速上涨7.74%。截至发稿,该股报0.430美元/股,成交量11.9759万股,换手率0.07%,振幅6.54%。X4制药股票所在的生物技术行业中,整体涨幅为0.19%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209223301ab6a0a7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209223301ab6a0a7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2489765239","title":"X4制药盘中异动 早盘股价大涨5.40%报0.410美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489765239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489765239?lang=zh_cn&edition=full","pubTime":"2024-12-06 22:52","pubTimestamp":1733496730,"startTime":"0","endTime":"0","summary":"北京时间2024年12月06日22时52分,X4制药股票出现异动,股价急速上涨5.40%。截至发稿,该股报0.410美元/股,成交量34.0524万股,换手率0.20%,振幅5.24%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-5.06倍。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。X4制药股票所在的生物技术行业中,整体涨幅为0.40%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206225210ab62e052&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206225210ab62e052&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2489111161","title":"X4制药盘中异动 大幅上涨5.08%报0.389美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489111161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489111161?lang=zh_cn&edition=full","pubTime":"2024-12-05 00:41","pubTimestamp":1733330499,"startTime":"0","endTime":"0","summary":"北京时间2024年12月05日00时41分,X4制药股票出现波动,股价快速拉升5.08%。截至发稿,该股报0.389美元/股,成交量70.7896万股,换手率0.42%,振幅5.71%。X4制药股票所在的生物技术行业中,整体涨幅为0.48%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120500413998e562e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120500413998e562e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2488942698","title":"X4制药盘中异动 早盘大幅跳水5.07%报0.352美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488942698","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488942698?lang=zh_cn&edition=full","pubTime":"2024-12-03 23:45","pubTimestamp":1733240739,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日23时45分,X4制药股票出现异动,股价快速下挫5.07%。截至发稿,该股报0.352美元/股,成交量39.5453万股,换手率0.23%,振幅8.87%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-4.47倍。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。X4制药股票所在的生物技术行业中,整体跌幅为0.49%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203234540971b618b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203234540971b618b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2488985035","title":"X4制药盘中异动 临近收盘股价大跌5.27%报0.372美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488985035","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488985035?lang=zh_cn&edition=full","pubTime":"2024-12-03 04:55","pubTimestamp":1733172926,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日04时55分,X4制药股票出现波动,股价快速跳水5.27%。截至发稿,该股报0.372美元/股,成交量156.049万股,换手率0.91%,振幅6.49%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-4.68倍。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。X4制药股票所在的生物技术行业中,整体涨幅为0.24%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203045527a267491b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203045527a267491b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2486807694","title":"X4制药盘中异动 临近收盘急速上涨5.02%报0.370美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486807694","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486807694?lang=zh_cn&edition=full","pubTime":"2024-11-28 04:55","pubTimestamp":1732740929,"startTime":"0","endTime":"0","summary":"北京时间2024年11月28日04时55分,X4制药股票出现异动,股价大幅拉升5.02%。截至发稿,该股报0.370美元/股,成交量110.78万股,换手率0.65%,振幅6.50%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-4.61倍。X4制药股票所在的生物技术行业中,整体涨幅为0.43%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128045529abe40a1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128045529abe40a1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2486310478","title":"X4制药盘中异动 大幅拉升5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486310478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486310478?lang=zh_cn&edition=full","pubTime":"2024-11-27 04:56","pubTimestamp":1732654571,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日04时56分,X4制药股票出现波动,股价急速上涨5.45%。截至发稿,该股报0.354美元/股,成交量85.2734万股,换手率0.50%,振幅4.95%。X4制药股票所在的生物技术行业中,整体涨幅为0.41%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127045611971a8b68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127045611971a8b68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2486036808","title":"X4制药盘中异动 早盘大幅上涨5.06%报0.355美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486036808","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486036808?lang=zh_cn&edition=full","pubTime":"2024-11-25 23:25","pubTimestamp":1732548357,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日23时25分,X4制药股票出现异动,股价快速拉升5.06%。截至发稿,该股报0.355美元/股,成交量34.031万股,换手率0.20%,振幅6.18%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-4.42倍。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。X4制药股票所在的生物技术行业中,整体涨幅为2.09%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125232557abde151d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125232557abde151d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2485710261","title":"X4制药盘中异动 大幅跳水5.18%报0.349美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485710261","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485710261?lang=zh_cn&edition=full","pubTime":"2024-11-22 22:41","pubTimestamp":1732286513,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日22时41分,X4制药股票出现波动,股价急速下跌5.18%。截至发稿,该股报0.349美元/股,成交量4.072万股,换手率0.02%,振幅3.96%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-4.43倍。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。X4制药股票所在的生物技术行业中,整体涨幅为0.28%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122224153971a81af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122224153971a81af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2485428783","title":"X4制药盘中异动 临近收盘股价大涨5.14%报0.358美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485428783","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485428783?lang=zh_cn&edition=full","pubTime":"2024-11-22 04:50","pubTimestamp":1732222259,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日04时50分,X4制药股票出现异动,股价急速上涨5.14%。截至发稿,该股报0.358美元/股,成交量114.007万股,换手率0.67%,振幅5.93%。最近的财报数据显示,该股实现营业收入560000.00美元,净利润-36.70百万美元,每股收益-0.18美元,毛利253000.00美元,市盈率-4.41倍。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。X4制药股票所在的生物技术行业中,整体涨幅为0.47%。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122045059971a7f47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122045059971a7f47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2485194854","title":"X4制药2024财年第三财季实现净利润-36.70百万美元,同比减少1488.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485194854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485194854?lang=zh_cn&edition=full","pubTime":"2024-11-22 00:00","pubTimestamp":1732204826,"startTime":"0","endTime":"0","summary":"11月22日,X4制药公布财报,公告显示公司2024财年第三财季净利润为-36.70百万美元,同比减少1488.74%;其中营业收入为560000.00美元,每股基本收益为-0.18美元。机构评级:截至2024年11月22日,当前有7家机构对X4制药目标价做出预测,其中目标均价为2.68美元,其中最低目标价为0.50美元,最高目标价为4.00美元。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122000038a24b9e4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122000038a24b9e4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR"],"gpt_icon":0},{"id":"2484438761","title":"X4制药盘中异动 早盘急速下挫7.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484438761","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484438761?lang=zh_cn&edition=full","pubTime":"2024-11-20 22:32","pubTimestamp":1732113177,"startTime":"0","endTime":"0","summary":"北京时间2024年11月20日22时32分,X4制药股票出现异动,股价急速下跌7.09%。截至发稿,该股报0.342美元/股,成交量17.873万股,换手率0.10%,振幅4.05%。X4制药股票所在的生物技术行业中,整体涨幅为0.37%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112022325798e43bd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112022325798e43bd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2484793156","title":"X4制药盘中异动 股价大跌7.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484793156","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484793156?lang=zh_cn&edition=full","pubTime":"2024-11-18 22:32","pubTimestamp":1731940341,"startTime":"0","endTime":"0","summary":"北京时间2024年11月18日22时32分,X4制药股票出现异动,股价大幅下跌7.46%。截至发稿,该股报0.373美元/股,成交量12.8654万股,换手率0.08%,振幅1.66%。X4制药股票所在的生物技术行业中,整体跌幅为0.30%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111822322195be486b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111822322195be486b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2483737473","title":"X4制药盘中异动 股价大跌5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483737473","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483737473?lang=zh_cn&edition=full","pubTime":"2024-11-15 22:31","pubTimestamp":1731681087,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日22时31分,X4制药股票出现波动,股价大幅跳水5.24%。截至发稿,该股报0.389美元/股,成交量49.6597万股,换手率0.29%,振幅5.24%。X4制药股票所在的生物技术行业中,整体跌幅为0.69%。X4制药公司简介:X4 Pharmaceuticals Inc 是一家后期临床生物制药公司,致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法,重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002,它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111522312798e42ebb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111522312798e42ebb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.x4pharma.com","stockEarnings":[{"period":"1week","weight":-0.1572},{"period":"1month","weight":0.7322},{"period":"3month","weight":-0.094},{"period":"6month","weight":-0.3652},{"period":"1year","weight":-0.1205},{"period":"ytd","weight":-0.2354}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"X4 Pharmaceuticals, Inc.于2010年8月2日根据特拉华州法律注册成立。该公司是一家晚期临床阶段的生物制药公司,发现和开发用于治疗罕见疾病和治疗选择有限的疾病的新疗法,重点关注免疫系统功能障碍导致的疾病。公司主导临床候选药物为mavorixafor,一种趋化因子受体CXCR4的小分子选择性拮抗剂。由于mavorixafor能够增加成熟、功能性白细胞进入血液的动员,他们认为mavorixafor有可能在多种慢性中性粒细胞减少性疾病中提供治疗益处,包括WHIM综合征,这是一种罕见的原发性免疫缺陷。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.003431},{"month":2,"riseRate":0.714286,"avgChangeRate":0.081966},{"month":3,"riseRate":0.571429,"avgChangeRate":0.137927},{"month":4,"riseRate":0.285714,"avgChangeRate":0.026234},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.016456},{"month":6,"riseRate":0.142857,"avgChangeRate":-0.244326},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.029016},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.090685},{"month":9,"riseRate":0.285714,"avgChangeRate":0.011165},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.121911},{"month":11,"riseRate":0.285714,"avgChangeRate":0.198505},{"month":12,"riseRate":0.375,"avgChangeRate":-0.097993}],"exchange":"NASDAQ","name":"X4制药","nameEN":"X4 Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"X4制药(XFOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供X4制药(XFOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"X4制药,XFOR,X4制药股票,X4制药股票老虎,X4制药股票老虎国际,X4制药行情,X4制药股票行情,X4制药股价,X4制药股市,X4制药股票价格,X4制药股票交易,X4制药股票购买,X4制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"X4制药(XFOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供X4制药(XFOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}